Skip to content
Clinical Whole-Genome Sequencing Services

Verifi Prenatal Test Services

What are the Verifi and Verifi Plus Prenatal Tests?

Verifi and Verifi Plus Prenatal Tests safely and noninvasively screen for the most common chromosomal aneuploidies as early as 10 weeks gestation using a single maternal blood draw. Verifi offerings provide the latest innovation in sequencing with a fast turnaround time, low failure rate, and accurate results.1

Verifi offers proven superiority to traditional screening methods for the screening of common fetal aneuploidies, with reduced false positive rates (increased specificity) and increased positive predictive values (PPV).1,2 Verifi has the lowest published failure rate in the industry—0.1%.1,3,4 Learn about evaluating test performance metrics for NIPT and view metrics for Verifi.

Physicians can order this Illumina service through our network of partner labs. Samples are processed at our CLIA-certified, CAP-accredited lab within 3-5 days. The physician will receive a report for use in discussing results and next steps with the patient.

Verifi Prenatal Test

The Verifi Prenatal Test is a non-invasive screening option for chromosomes 13, 18, and 21, and fetal sex chromosome aneuploidies in both singleton and twin pregnancies

Highlights:
  • Better than serum screen (fewer false positives)2,5,6
  • Fast turnaround time (3-5 days)
  • Low failure rate and high accuracy1
Get the facts

Learn more about test options and read sample reports from the Verifi Prenatal Test.

View Verifi Prenatal Test handout
Testing indications:
  • Advanced maternal age (> 35 years)
  • Positive serum screen
  • Abnormal ultrasound
  • History suggestive of increased risk for the specified chromosome aneuploidies
  • Low risk/maternal anxiety
Screens for:
  • Trisomy 21 (Down syndrome)
  • Trisomy 18 (Edwards syndrome)
  • Trisomy 13 (Patau syndrome)
  • Fetal sex aneuploidies

Verifi Plus Prenatal Test

The Verifi Plus Prenatal Test contains everything in the Verifi Prenatal Test and includes additional panels. It is a non-invasive screening option for standard chromosome aneuploidies, certain microdeletions, and all autosomes. Expanded panels (microdeletions or all autosomes) are optional add-ons for singleton pregnancies.

Highlights:

Verifi Plus screens for more chromosome conditions than Verifi.

Testing indications:

Women who decline an invasive procedure in the presence of an abnormal ultrasound.

Get the facts

Learn more about test options and read sample reports from the Verifi Plus Prenatal Test.

View Verifi Plus Prenatal Test handout
View Verifi Plus Prenatal Test brochure

Available optional add-on offerings include:

Sex chromosome aneuploidies

  • Monosomy X (MX; Turner syndrome)
  • XXX (Triple X)
  • XXY (Klinefelter syndrome)
  • XYY (Jacobs syndrome)

Expanded autosomal trisomies

  • All chromosomes

Microdeletion syndromes

  • 1p36 deletion
  • 4p- (Wolf-Hirschhorn syndrome)
  • 5p- (cri-du-chat syndrome)
  • 15q11 (Prader-Willi syndrome/Angelman syndrome)
  • 22q11 deletion (DiGeorge)
Additional information

For questions about the Illumina Clinical Services Laboratory, contact us by phone at (858) 736-8080 or (855) 266-6563 (toll-free), or by submitting a ticket.

Interested in receiving newsletters, case studies, and information on new applications? Enter your email address.
References
  1. Taneja PA, Snyder HL, de Feo E, et al. Noninvasive prenatal testing in the general obstetric population: clinical performance and counseling considerations in over 85 000 cases. Prenat Diagn. 2016;36(3):237-243.
  2. Bianchi DW, Parker RL, Wentworth J, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370(9):799-808.
  3. McCullough RM, Almasri EA, Guan X, et al. Non-invasive prenatal chromosomal aneuploidy testing--clinical experience: 100,000 clinical samples. PLoS One. 2014;9(10):e109173.
  4. Ryan A, Hunkapiller N, Banjevic M, et al. Validation of an enhanced version of a single-nucleotide polymorphism-based noninvasive prenatal test for detection of fetal aneuploidies. Fetal Diagn Ther. 2016;40(3):219-223.
  5. Dungan, J.S. et al. Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general- risk population: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. 25, 100336 (2023).
  6. Practice Bulletin No. 163: Screening for Fetal Aneuploidy. Obstet Gynecol. 2016;127(5):979-981.

Verifi™ and Verifi™ Plus were developed by, and their performance characteristics were determined by Verinata Health, Inc. (VHI) a wholly owned subsidiary of Illumina, Inc. The VHI laboratory is CAP-accredited and certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. They have not been cleared or approved by the U.S. Food and Drug Administration.

For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.